Combination of Chinese Herbal Medicines and Conventional Treatment versus Conventional Treatment Alone in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention (5C Trial): An Open-Label Randomized Controlled, Multicenter Study
机构：[1]Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China[2]Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China[3]Zhongshan Hospital, Fudan University, Shanghai 200032, China[4]Beijing Anzhen Hospital, Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing 10029, China首都医科大学附属安贞医院北京朝阳医院[5]Cardiovascular Institute & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College,Beijing 100037, China[6]Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China首都医科大学附属北京同仁医院首都医科大学附属同仁医院[7]Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100007, China[8]The Affiliated Hospital of Liaoning Traditional Chinese Medicine University, Shenyang 110033, China[9]Beijing Chinese Medicine Hospital, Capital Medical University, Beijing 100010, China[10]First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China[11]Beijing Chuiyangliu Hospital, Beijing 100022, China[12]The Second People’s Hospital of Fujian Province, Fuzhou 350100, China[13]Wuxi Traditional Chinese Medicine Hospital, Nanjing University of Traditional Chinese Medicine, Wuxi 214001, China
Aims. To evaluate the efficacy of Chinese herbal medicines (CHMs) plus conventional treatment in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods and Results. Participants (n = 808) with ACS who underwent PCI from thirteen hospitals of mainland China were randomized into two groups: CHMs plus conventional treatment group (treatment group) or conventional treatment alone group (control group). All participants received conventional treatment, and participants in treatment group additionally received CHMs for six months. The primary endpoint was the composite of cardiac death, nonfatal recurrent MI, and ischemia-driven revascularization. Secondary endpoint was the composite of readmission for ACS, stroke, or congestive heart failure. The safety endpoint involved occurrence of major bleeding events. The incidence of primary endpoint was 2.7% in treatment group versus 6.2% in control group (HR, 0.43; 95% CI, 0.21 to 0.87; n = 0.015). The incidence of secondary endpoint was 3.5% in treatment group versus 8.7% in control group (HR, 0.39; 95% CI, 0.21 to 0.72; P = 0.002). No major bleeding events were observed in any participant. Conclusion. Treatment with CHMs plus conventional treatment further reduced the occurrence of cardiovascular events in patients with ACS after PCI without increasing risk of major bleeding.
基金：
Supporting
Program of the “Eleventh Five-year Plan” for Sci & Tech
Research of China (no. 2006BA104A01).
第一作者机构：[1]Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Shao-Li Wang,Cheng-Long Wang,Pei-Li Wang,et al.Combination of Chinese Herbal Medicines and Conventional Treatment versus Conventional Treatment Alone in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention (5C Trial): An Open-Label Randomized Controlled, Multicenter Study[J].EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE.2013,2013:doi:10.1155/2013/741518.
APA：
Shao-Li Wang,Cheng-Long Wang,Pei-Li Wang,Hao Xu,Hong-Ying Liu...&Ke-Ji Chen.(2013).Combination of Chinese Herbal Medicines and Conventional Treatment versus Conventional Treatment Alone in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention (5C Trial): An Open-Label Randomized Controlled, Multicenter Study.EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE,2013,
MLA：
Shao-Li Wang,et al."Combination of Chinese Herbal Medicines and Conventional Treatment versus Conventional Treatment Alone in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention (5C Trial): An Open-Label Randomized Controlled, Multicenter Study".EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2013.(2013)
